Search results for "Positive pressure ventilation"
showing 6 items of 6 documents
2020
Nasal continuous positive airway pressure (NCPAP) devices using variable (vf-) and continuous (cf-) flow or synchronized nasal intermittent positive pressure ventilation (s-NIPPV) are used to prevent or treat intermittent hypoxia (IH) in preterm infants. Results concerning which is most effective vary. We aimed to investigate the effect of s-NIPPV and vf-NCPAP compared to cf-NCPAP on the rate of IH episodes. Preterm infants with a gestational age of 24.9–29.7 weeks presenting with IH while being treated with cf-NCPAP were monitored for eight hours, then randomized to eight hours of treatment with vf-NCPAP or s-NIPPV. Data from 16 infants were analyzed. Due to an unexpectedly low sample size…
Perioperative Adverse Events in Obstructive Sleep Apnea and Use of Noninvasive Mechanical Ventilation: Key Topics and Clinical Implications
2016
Obstructive sleep apnea (OSA) is a common public health care problem and, yet, the perioperative management of OSA remains inadequate. Patients affected by this condition are prone to early postoperative complications, in part due to the negative effects of sedative, analgesic, and anesthetic agents on pharyngeal tone and arousal responses to hypoxia, hypercapnia, and obstruction. The use of opioids may also contribute to late adverse events, mainly by suppressing the rapid eye movement phase of sleep. As a result, preoperative screening of patients at high risk of OSA, as well as the implementation of a perioperative strategy to reduce the risk of complications, should lead to early periop…
Noninvasive Ventilation in the Perioperative Period
2019
High-flow nasal therapy (HFNT), as well as noninvasive ventilation (NIV), represents both noninvasive supports. HFNT is a ventilator support where humidified and heated gases are administered to the patient’s airways by a small nasal cannula at flow that reach up to 60 L/min. The delivered flow can be combined with oxygen providing different inspiratory oxygen fractions (FiO2). HFNT is increasingly used for critically ill adult patients in different clinical settings. Differently from noninvasive ventilation (NIV) which is intended to deliver intermittent positive pressure ventilation (NIPPV) or continuous positive airway pressure (CPAP) to the patient’s airway via different external interf…
The right interface for the right patient in noninvasive ventilation: a systematic review
2022
Introduction Research in the field of noninvasive ventilation (NIV) has contributed to the development of new NIV interfaces. However, interface tolerance plays a crucial role in determining the beneficial effects of NIV therapy. Areas covered This systematic review explores the most significant scientific research on NIV interfaces, with a focus on the potential impact that their design might have on treatment adherence and clinical outcomes. The rationale on the choice of the right interface among the wide variety of devices that are currently available is discussed here. Expert opinion The paradigm 'The right mask for the right patient' seems to be difficult to achieve in real life. Rang…
Noninvasive Ventilation in Critically Ill Patients
2015
Since its first application in the late 1980s, noninvasive ventilation (NIV) has been the first-line intervention for certain forms of acute respiratory failure. NIV may be delivered through the patient's mouth, nose, or both using noninvasive intermittent positive pressure ventilation or continuous positive airway pressure. When applied appropriately, NIV may reduce morbidity and mortality and may avert iatrogenic complications and infections associated with invasive mechanical ventilation. This article provides physicians and respiratory therapists with a comprehensive, practical guideline for using NIV in critical care. © 2015 Elsevier Inc.
Noninvasive Positive Pressure Ventilation in Amyotrophic Lateral Sclerosis
2010
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of unknown origin that affects approximately 1.5 individuals per 100,000 every year; usually, these individuals are between 55 and 75 years of age [1]. ALS causes progressive weakness of voluntary muscle groups, including respiratory ones, and respiratory failure or pneumonia related to respiratory muscle weakness is the most frequent cause of death.